# US 2024/0197841 A1 · Formulations of l-asparaginase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197841 A1
- Document ID: US20240197841A1
- Status: Published application
- Kind: A1
- Application number: 18/285,209
- Filed: 2022-04-05
- Published: 2024-06-20
- Earliest claimed: 2021-03-29
- Assignees: Jazz Pharmaceuticals Ireland Limited
- Applicants: Jazz Pharmaceuticals Ireland Ltd.
- Inventors: Sekhar Kanapuram; Haripada Maity; Guifeng Jiang; Roja Narwal
- Web page: https://patentgrep.com/patent/US20240197841A1

## CPC

- A61K 38/50: acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/02: Inorganic compounds
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein are stable, aqueous, non-lyophilized formulations of L-asparaginase. Also provided herein are methods of using such formulations in the treatment of one or more diseases, disorders, or conditions (for example, cancers such as Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)) that are treatable by asparagine depletion.

## Claims

### Claim 1

An aqueous, non-lyophilized formulation, comprising:
(i) an L-asparaginase, wherein the L-asparaginase comprises four monomer units, wherein each monomer unit has an amino acid sequence that is at least about 70% identical to SEQ ID NO: 1; and
(ii) one or more stabilizers, or one or more buffers, or any combination thereof.

### Claim 2 (depends on 1)

The formulation of claim 1, wherein the one or more stabilizers comprise one or more disaccharides, one or more sorbitols, one or more amino acids, or any combination thereof.

### Claim 3 (depends on 2)

The formulation of claim 2, wherein the one or more disaccharides comprise trehalose, sucrose, or any combination thereof.

### Claim 4 (depends on 1)

The formulation of claim 1, wherein the one or more buffers are substantially free of amino acid.

### Claim 5 (depends on 1)

The formulation of claim 1, wherein the formulation comprises:
a) less than about 0.6% low-molecular-weight (LMW) species after storage at 40° C. for two months;
b) less than about 0.6% LMW species after storage at 37° ° C. for one week;
c) less than 2% high-molecular-weight (HMW) species after storage at 40° C. for two months; or
d) a combination thereof.

### Claim at position 6

6-7. (canceled)

### Claim 8 (depends on 1)

The formulation of claim 1, wherein the L-asparaginase is present at a concentration of about 20 mg/mL.

### Claim 9 (depends on 1)

The formulation of claim 1, wherein the L-asparaginase is non-PEGylated and non-PASylated.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The formulation of claim 1, wherein:
a) the one or more buffers comprise a phosphate buffer, an acetate buffer, or any combination thereof;
b) the one or more buffers are present at a concentration of between about 0.5 mM and 50 mM; or
c) a combination thereof.

### Claim 12

(canceled)

### Claim 13 (depends on 11)

The formulation of claim 11, wherein the one or more buffers comprise sodium phosphate.

### Claim at position 13

14-15. (canceled)

### Claim 16 (depends on 1)

The formulation of claim 1 wherein the formulation further comprises sodium chloride.

### Claim 17 (depends on 16)

The formulation of claim 16, wherein the sodium chloride is present at a concentration of between 25 mM and about 150 mM.

### Claim 18 (depends on 1)

The formulation of claim 1, wherein the formulation further comprises one or more excipients.

### Claim 19 (depends on 18)

The formulation of claim 18, wherein:
a) the one or more excipients comprise polysorbate 80, polysorbate 20, poloxamer 188, or any combination thereof;
b) the one or more excipients are present at a concentration of between about 0.004% (w/v) and about 0.3% (w/v); or
c) a combination thereof.

### Claim 20

(canceled)

### Claim 21 (depends on 1)

The formulation of claim 1, wherein the formulation has a pH of between about 4.0 and about 8.5.

### Claim 22

A method of treating a disease, condition, or disorder that is treatable by asparagine depletion in a subject in need thereof, comprising administering to the subject an aqueous, non-lyophilized formulation, comprising:
i) an L-asparaginase, wherein the L-asparaginase comprises four monomer units, wherein each monomer unit has an amino acid sequence that is at least about 70% identical to SEQ ID NO: 1; and
ii) one or more stabilizers, or one or more buffers, or any combination thereof.

### Claim 23 (depends on 22)

The method of claim 22, wherein the disease, condition, or disorder is cancer.

### Claim 24 (depends on 23)

The method of claim 23, wherein the cancer is acute lymphoblastic leukemia (ALL), relapsed ALL, lymphoblastic lymphoma (LBL), or relapsed LBL.

### Claim at position 23

25-27. (canceled)

### Claim 28 (depends on 22)

The method of claim 22, wherein the formulation is administered intramuscularly, intravenously, or subcutaneously.

### Claim at position 25

29-30. (canceled)

### Claim 31 (depends on 22)

The method of claim 22, wherein the formulation is co-administered with one or more other chemotherapeutic agents.

### Claim 32

A kit, comprising:
a) an aqueous, non-lyophilized formulation, comprising:
i) an L-asparaginase, wherein the L-asparaginase comprises four monomer units, wherein each monomer unit has an amino acid sequence that is at least about 70% identical to SEQ ID NO: 1, and
ii) one or more stabilizers, or one or more buffers, or any combination thereof; and
b) instructions for treating a disease, condition, or disorder that is treatable by asparagine depletion in a subject in need thereof.

### Claim at position 28

33-38. (canceled)
